A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery

Evan Rosenbaum, Rashmi Chugh, Christopher W. Ryan, Mark Agulnik, Mohammed Milhem, Suzanne George, Robin L. Jones, Bartosz Chmielowski, Brian A. Van Tine, Hussein A. Tawbi, Anthony Elias, William L. Read, G. Thomas Budd, Li‐Xuan Qin, Eve T. Rodler, Joe Hirman, Paul L. Weiden, Cathryn M. Bennett, Philip O. Livingston, Govind Ragupathi, David E. Hansen, Sandra P. D’Angelo, William D. Tap, Gary K. Schwartz, Robert G. Maki, Richard D. Carvajal